Reneuron Share Discussion Threads

[heyho2] 17/9/2013 20:56

Title says it all really!

[peawacks] 14/9/2013 10:00

http//www.scotsman.com/business/management/reneuron-picks-roslin-for-stem-cells-trials-1-3092723

[dmhzx] 13/9/2013 18:58

What sort of Hunt parant names their son Mike: - Especially since they probably saw "American Graffiti": - Has anyone seen Mike Hunt

[peawacks] 11/9/2013 11:24

heyho2,
thanks !

[deltar] 11/9/2013 10:48

RF - buy on lows......

[pedr01] 10/9/2013 13:20

3843: Hindsight is such a wonderful thing .... Hahahahahahaha

[heyho2] 10/9/2013 13:13

More evidence to support the use of Reneuron's CTX Stem Cells (it's the bit about exosomes that is interesting) for the treatment of Stroke sufferers, summary first:



... and then the techy bit:

[rocket fuel] 07/9/2013 10:19

thats interesting on the gilt return compared to rene.

at least you would have made a turn MP because for every £1000 you invested in rene when they floated 8 yrs ago (for the second bite of the AIM cherry) you would have lost 86% of your initial capital if you needed/wanted to cash in your hard earned by yesterdays bell.

buy 4000 shares for 25p each at ipo in August 2005 = £1000

sell same 4000 shares at yesterdays close for 3.5p (on the bid) = £140

86% drop

if you believed in this company from day one and invested £50k for the long term (8 yrs) and had to cash in yesterday, you would have been handed £7k back. (£43,000 loss, ouch!)

on the other hand:

£50k invested in gilts on the same day with compounded (variable) yearly interest rates added on, and you had to cash in yesterday, you would be handed back c£65k (£15,000 gain, nice.)

so, using your gilts scenario, you would be £58k better off than the man that went for rene.

and imo as the months roll on and the cash gets thinner the gulf between those two examples will become greater.

will not be surprised if i see 1p and sub 1p here in time.
would not be at all surprised if i see it test £10m mkt cap within 12 months.

just my observations.

[monty panesar] 06/9/2013 23:26

Biotech doesn't seem your game. Now that gilts yield 3pc pa it might be worth looking at them.

[rocket fuel] 06/9/2013 23:18

MP, I can assure you I have never bough a rene share in my life nor do I have a chip on my shoulder but I have followed the company over the past few years with interest.

who called the massive 1bn placing?

as for 1p that is fair value for this r&d company imo (£17m) and the share price will correct down accordingly over a period of coming months.

the cash will burn like wildfire along with the share price
no revenue and nothing going through the FDA pipeline for years to come.
who will front up the next £70 - £100 million they will need to take them through three sets of phase 3 trials and on thru FDA approval 5/6 years down the line?

[monty panesar] 06/9/2013 22:57

Rocket fuel.You have called this stock so wrong I am amazed you can still show your face. I remember the massive dilution coming at 1p- only a multiple or 2 out.

Why do I think you invested a lot of money at a much higher price and now have a massive chip on your shoulder??? :) time you grow up.

[rocket fuel] 06/9/2013 22:40

still no rns confirmation on who is going to manufacture and supply the 001 CTX cell product needed to commence phase 2 pisces trials. have they validated a new supplier yet?
good old dr harpic left you in the lurch on that one when he done the highland fling out the back door of Pentlands just before the lights went out.
nhsbt will cover you for the CTXcryo cell product that you will be using for 009 trials but no good for 001 trials.
i guess they will be looking stateside for a contractor to manufacture and suplpy the lead CTX product now they have plenty of cash available to be jetting 1st class over the water on a 5 star regualar basis.

imo the science will survive and prosper but the company as you know it will not.

[rocket fuel] 05/9/2013 12:08

cash burning at an alarming rate and nothing doing in clinical trials for a long while yet. I would say December at the earliest if you're lucky.
tick tock, come spring 2015 and the begging bowl will be doing the rounds again.

www.clinicaltrials.gov/ct2/results?term=Reneuron&Search=Search

[stewart_25] 02/9/2013 16:13

more good news and the share price goes down nearly 10% - this share beggers belief!!

[heyho2] 01/9/2013 23:08

The age of regenerative medicine has arrived:

[heyho2] 30/8/2013 17:50

Interesting and informative interview with Michael Hunt (CEO) about recent developments including the fund raising and developments for ReN003:

[earnestwipplethwaiteiii] 29/8/2013 11:29

All the traders are wetting their knickers over at REM.

[norbus] 29/8/2013 10:52

Placees likely to have expected it

[peawacks] 29/8/2013 09:18

Good news, completely disregarded by the market.

[mirabeau] 29/8/2013 07:42

This is a very interesting news release.

[qpr67] 29/8/2013 07:40

ReNeuron Group plc Orphan Drug Designation
Print
Alert
TIDMRENE

RNS Number : 6882M

ReNeuron Group plc

29 August 2013


29 August 2013 AIM: RENE

ReNeuron receives European and US Orphan Drug Designation for its retinal stem cell therapy candidate for treatment of retinitis pigmentosa

Guildford, UK, 29 August 2013: ReNeuron Group plc (the "Company") (AIM: RENE.L) is pleased to announce that its ReN003 retinal stem cell therapy candidate for retinitis pigmentosa has achieved a significant regulatory milestone. The therapy has been granted Orphan Drug Designation in both Europe and the US by the European Commission and the Food and Drug Administration, respectively.

Orphan Drug Designation is typically granted to treatments that provide significant benefit to patients with rare diseases that are life-threatening or chronically debilitating. Treatments with this designation benefit from significant commercial and regulatory advantages such as market exclusivity for 10 years from approval in the disease concerned, against other treatments offering no greater therapeutic advantage.

ReNeuron is using its proprietary human retinal progenitor cells as the basis of its ReN003 therapeutic candidate targeting retinitis pigmentosa, a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying. Retinitis pigmentosa affects approximately 4 in 10,000 people in the EU and US.

The late pre-clinical development of the ReN003 programme also benefits from a recently awarded GBP0.8 million Biomedical Catalyst grant from the UK Technology Strategy Board. The Company is targeting an initial Phase I/II clinical trial with ReN003 in the UK and the US, in retinitis pigmentosa patients, with clinical trial applications expected to be filed in the middle part of 2014.

Michael Hunt, Chief Executive Officer of ReNeuron, said:

"We are delighted to have received Orphan Drug Designation for our ReN003 stem cell therapy candidate for retinitis pigmentosa from both the European Commission in Europe and the FDA in the US. Orphan status diseases are an increasing area of therapeutic and commercial focus by the mainstream pharmaceutical industry due to the distinct regulatory and market exclusivity advantages that Orphan Drug Designation confers. This fact bodes well for the commercial potential of our ReN003 therapy."